Annual report pursuant to Section 13 and 15(d)

Schedule of Restricted Stock Award Activity (Details)

v3.22.4
Schedule of Restricted Stock Award Activity (Details) - Restricted Stock [Member] - $ / shares
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of Restricted Stock Awards, Outstanding Beginning 1,940,740 [1]
Weighted Average Grant Date Fair Value, Outstanding Beginning $ 12.76 [1]
Number of Restricted Stock Awards, Granted 320,000 1,947,795
Weighted Average Grant Date Fair Value, Granted $ 4.53 $ 12.76
Number of Restricted Stock Awards, Vested 169,320
Weighted Average Grant Date Fair Value, Vested $ 13.48
Number of Restricted Stock Awards, Forfeited (7,055)
Weighted Average Grant Date Fair Value, Forfeited $ 13.11
Number of Restricted Stock Awards, Outstanding Ending [1] 2,091,420 1,940,740
Weighted Average Grant Date Fair Value, Outstanding Ending [1] $ 11.44 $ 12.76
Number of Restricted Stock Awards, Vested (169,320)
[1] The unvested restricted stock awards presented in the table above, are inclusive of 50,000 restricted stock awards granted outside the Lucid Diagnostics Inc. 2018 Equity Plan as of December 31, 2022 and December 31, 2021.